Geo News
Community curated by people like you
LatestAICryptoHealthWorld AffairsUS Politics

Medication adherence stories

Aug 5, 2026

Study finds diabetes drug tirzepatide reduces heart attack and stroke risk in high-risk patients

New research published in The BMJ shows that tirzepatide (Mounjaro), a GLP-1 receptor agonist, reduces the risk of major cardiovascular events by 33% in type 2 diabetes patients with existing heart disease. A separate study also found that consistent medication adherence among diabetes patients reduces heart disease risk by 27%.

Aug 5, 2026·11 sources
00

Study finds diabetes drug tirzepatide reduces heart attack and stroke risk in high-risk patients

New research published in The BMJ shows that tirzepatide (Mounjaro), a GLP-1 receptor agonist, reduces the risk of major cardiovascular events by 33% in type 2 diabetes patients with existing heart disease. A separate study also found that consistent medication adherence among diabetes patients reduces heart disease risk by 27%.

Aug 5, 2026·9 sources
00

Top claims

  • ▪In the BMJ study cohort, 35,353 patients started tirzepatide and 17,618 started sitagliptin, with outcomes monitored from the first day of treatment up to one year.
  • ▪Researchers of the BMJ study chose sitagliptin as a neutral placebo proxy because several prior studies have shown it has no effect on cardiovascular outcomes.
  • ▪Researchers Nils Krüger and colleagues stated that trial-anchored evidence from clinical practice can estimate the expected cardiovascular benefits of tirzepatide to inform shared decision-making.

Subtopics

Cardiovascular health.2GLP-1 medications2Drug Approval and Clinical Trials1

Related timelines

Congress

108 stories

Payments

118 stories

Russia-Ukraine war

136 stories

Trump administration

116 stories

US health policy & drug pricing

123 stories